Results 1–20 of 221 for pfizer

Written Answers — Department of Health: Epilepsy: Drugs (14 Mar 2017)

Alex Chalk: To ask the Secretary of State for Health, whether the Government is able to allocate Competition and Markets Authority fines collected from pharmaceutical manufacturers Pfizer and distributor Flynn Pharma for the purposes of research and treatment for epilepsy patients.

O’Neill Review — [Mr Gary Streeter in the Chair] (7 Mar 2017)

Kevin Hollinrake: ...return, it is difficult for pharmaceutical companies to invest in this field, although some are. For example, AstraZeneca recently sold its late-stage small molecule antibiotic business to Pfizer and so stepped out of research and development, but others, such as MSD, are still investing. It cannot be right that some companies are willing to invest—perhaps for altruistic...

Written Answers — Department of Health: Palbociclib (23 Feb 2017)

Simon Burns: To ask the Secretary of State for Health, what meetings representatives from NICE (a) have had and (b) plan to have with Pfizer during the consultation period for palbociclib (Ibrance) since the publication of the draft guidance on that drug on 3 February 2017.

Health Service Medical Supplies (Costs) Bill - Report (7 Feb 2017)

Lord Warner: ...I fully support the Government acting through the Bill to prevent the NHS being blatantly ripped off under the statutory scheme when a branded drug comes off patent, as happened with Flynn Pharma when a Pfizer anti-epilepsy drug came off patent. The ABPI has never challenged actions in cases of this kind. However, the broad wording of the Bill goes well beyond closing this particular...

Oral Answers to Questions — Treasury: Single Market (17 Jan 2017)

Julian Brazier: ...welcome my hon. Friend’s typically constructive approach, but does she recall the clinical trials directive that destroyed much of the pharmaceutical industry in this country overnight, including Pfizer’s site in east Kent?

Health Service Medical Supplies (Costs) Bill - Second Reading (21 Dec 2016)

Lord Hunt of Kings Heath: ...O’Shaughnessy, to his new post. He will enjoy taking the Bill through its remaining stages—perhaps. As noble Lords have said, the recent fines imposed by the Competition and Markets Authority on Pfizer and Flynn Pharma for charging the NHS excessive prices is a salutary warning to the pharmaceutical industry. We certainly welcome the provisions in the Bill that deal with the...

Public Bill Committee: Health Service Medical Supplies (Costs) Bill: Review of extending provisions to repurposed off-patent drugs (15 Nov 2016)

Philippa Whitford: pregabalin. The commonest use of that is for neuropathic pain: people who have had nerve damage from surgery or trauma and have difficult-to-control pain. The drug was originally designed for epilepsy, and Pfizer, which makes it, managed to get a court order saying that the patent on its use for neuropathic pain would continue to 2017 and that it would sue general practitioners who...

Drug-Resistant Infections - Motion to Take Note (15 Sep 2016)

Lord Hunt of Kings Heath: ...say a little more about the progress that is being made in those discussions? Vaccines have been mentioned by a number of noble Lords. I have had a comment from one of the companies that have briefed me—it was from Pfizer, in fact—that while the UK is a world leader in national immunisation programmes, its sense is that immunisation is not regarded by the Government as an,...

Previous Business – Commons: Select Committee (14 Sep 2016)

Sub-Committee on Education, Skills and the Economy: Apprenticeships. 2:15 pm; Room 16, Palace of Westminster
Witnesses: ...and Skills, British Chambers of Commerce Iain Murray, Senior Policy Officer, TUC Ben Willmott, Head of Public Policy, Chartered Institute of Personnel and Development Liz Greenfield, Head of HR, Pfizer Councillor Robert Light, Vice Chair of City Regions Board, Local Government Association Iain McIlwee, Chief Executive, British Woodworking Federation

Teachers: Academies and Free Schools - Question for Short Debate (12 Sep 2016)

Lord Suri: ...our economic future. In order to provide the best technical education, these schools need to attract the best talent from our universities and firms. For a young graduate who may have offers from, say, Rolls-Royce or Pfizer, having to go through the route of getting another degree may turn them off the profession altogether. Surely noble Lords will see the foolishness of such a move. I...

Fourth Industrial Revolution (8 Sep 2016)

Stephen Kinnock: view, we need to reform the Companies Act, placing a clear national interest clause and a method of monitoring and executing that clause, so that we move away from situations such as we saw with Pfizer attempting to take AstraZeneca. I am very thankful that the previous Leader of the Opposition did a great job in preventing that from happening, but it is very ad hoc and we need a...

Written Answers — Department of Health: NHS: Drugs (13 Jun 2016)

Alistair Burt: ...Ltd CM/PHR/10/5203 Pan London Antiretroviral 2013 Gilead Sciences Ltd CM/PHR/10/5203 Pan London Antiretroviral 2014 Gilead Sciences Ltd CM/PHR/10/5203 Pan London Antiretroviral 2015 Pfizer Limited CM/PHR/13/5415 Branded Pharmaceutical Products - National (05-2014) Source: Department of Health Commercial Medicines Unit 1 Based on pre-agreement estimated values for framework...

Oral Answers to Questions — Prime Minister: Engagements (8 Jun 2016)

Craig Mackinlay: My right hon. Friend will be aware that it is five years since the announcement by Pfizer in Sandwich that it would scale down operations. Since then, with enterprise zone status, there has been a true renaissance of high-tech businesses on the site, and employment levels are now nearly up to where they were previously. My right hon. Friend has previously promised a trip to South Thanet. May...

Tax Avoidance and Evasion (13 Apr 2016)

Robert Jenrick: ...behaviour, both by individuals and corporations. Corporation tax at 17%, versus 30% in the United States, will be a major step forward. Only the other day, President Obama was forced to take action against Pfizer because of its motivation to move to lower tax jurisdictions because of the 30% corporation tax in the United States. There is more to do. I do not stand here for one minute...

Access to Medical Treatments (Innovation) Bill: Second Reading (26 Feb 2016)

Lord Freyberg: ...options. The evidence for this can be seen in France, where the Institut National du Cancer has been driving a national molecular pathology programme for over a decade. It is the preferred European partner for large pharma like Pfizer for late-stage clinical trials in precision oncology. That investment also created equality of access to modern molecular diagnostic technologies and...

Opposition Day — [15th Allotted Day] — Trade, Exports, Innovation and Productivity (13 Jan 2016)

Stephen Kinnock: The hon. Gentleman is making an interesting and important point about foreign takeovers, particularly hostile takeovers. One of the important ones recently was Pfizer’s attempt to take over AstraZeneca. I am sure he agrees that that case concluded in absolutely the right way, by protecting one of the great British assets and enabling it to continue its long-term strategies of investment...

Business of the House (3 Dec 2015)

Chris Bryant: “Doctor Who” you have secretly had some kind of feeding and filtration system fitted into the chair or some hidden tubes. Or perhaps it is down to drugs. Now that the pharmaceutical giants Pfizer and Allergan, the owners of Viagra and Botox, have come together, perhaps they have invented a new drug, with which you have been impregnated, Mr Speaker, which means that you can...

Foreign Ownership of UK Assets — Motion to Take Note (19 Nov 2015)

the Earl of Courtown: ...UK average. Her Majesty’s Government will go further by supporting the resurgence of strong city regions through devolution, enabling cities to work together to take responsibility for their own economic success. The noble Lords, Lord Haskel and Lord Mendelsohn, also mentioned the Pfizer interest in AstraZeneca as being an example of corporate investment short-termism. I do not...

[Geraint Davies in the Chair] — Tropical Diseases (27 Oct 2015)

Jeremy Lefroy: ...donated nearly 2 billion tablets of albendazole for lymphatic filariasis and will continue until elimination, and has also donated 1 billion per annum to de-worm school-aged children. Johnson & Johnson has donated 200 million tablets of mebendazole a year. Pfizer donated 70 million doses of azithromycin for trachoma in 2012 alone. Novartis has donated drugs for leprosy. Eisai, the...

1 2 3 4 5 6 7 8 9 10 > >>

Create an alert

Did you find what you were looking for?

Advanced search

Find this exact word or phrase

You can also do this from the main search box by putting exact words in quotes: like "cycling" or "hutton report"

By default, we show words related to your search term, like “cycle” and “cycles” in a search for cycling. Putting the word in quotes, like "cycling", will stop this.

Excluding these words

You can also do this from the main search box by putting a minus sign before words you don’t want: like hunting -fox

We also support a bunch of boolean search modifiers, like AND and NEAR, for precise searching.

Date range


You can give a start date, an end date, or both to restrict results to a particular date range. A missing end date implies the current date, and a missing start date implies the oldest date we have in the system. Dates can be entered in any format you wish, e.g. 3rd March 2007 or 17/10/1989


Enter a name here to restrict results to contributions only by that person.


Restrict results to a particular parliament or assembly that we cover (e.g. the Scottish Parliament), or a particular type of data within an institution, such as Commons Written Answers.


If you know the actual Hansard column number of the information you are interested in (perhaps you’re looking up a paper reference), you can restrict results to that; you can also use column:123 in the main search box.